Drug Trial Radar · NCT07220902
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,240
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2033
Study completion Jul 2034
Sponsor
- Lead sponsor
- Nebraska Methodist Health SystemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including: severe allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.
Conditions
- Severe Preeclampsia
- Eclampsia Preeclampsia
Interventions
LevetiracetamDrug
1g oral loading dose followed by 300mg q 8 hours beginning 8 hours after loading dose.
magnesium sulfateDrug
4gram bolus followed by 2g per hour continuous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eclamptic SeizureTime frame: From enrollment until then end of monitoring at 6 weeks postpartum.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Methodist Women's Hospital
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.